Increasing skills and the availability of raw materials would be a bigger boost for vaccine production right now.
Articles on TRIPS agreement
Displaying 21 - 32 of 32 articles
Australia has joined a handful of countries resisting a push to relax intellectual property rules related to COVID vaccines.
A waiver may not allow all developing countries to secure medicines and other anti-COVID technologies in a timely way.
A waiver on some intellectual property rules at the WTO for COVID-19 vaccines would ensure more equitable access, but wouldn’t solve all the problems facing developing countries.
The TRIPS waiver makes COVID-19 treatments more accessible globally by enabling manufacture and distribution of COVID-19 drugs and medical supplies that would normally be protected by patents.
There’s a risk Australia won’t get access to everything it will need need. It can take are simple stepsto make sure patents don’t get in the way.
After nearly two decades of legal battles and negotiations, South Africa is moving to cut the cost of medicines with policies to increase imports and local production of generic drugs.
There is a window of opportunity for the least developed countries to develop their own pharmaceuticals industry.
Seven rounds of negotiations for the Regional Comprehensive Economic Partnership have already taken place with virtually no public debate. The next round of negotiations begins today in Kyoto, Japan.
India is the global focal point for legal and political struggles over patent rights and access to medicines. Particular attention is focused on the Swiss pharmaceutical giant Novartis, which is in battle…
Two large multinational pharmaceutical companies are fighting for patents and monopoly pricing in Indian courts. The outcomes of the cases – involving Novartis and Bayer – are likely to determine the country’s…
The Anti-Counterfeiting Trade Agreement (ACTA) 2011 - Twitter hashtag #ACTA - is a controversial trade agreement designed to provide for stronger enforcement of intellectual property rights. There’s been…
Top contributors
-
Professor of Public Health, La Trobe University
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Professor of Intellectual Property Law, City St George's, University of London
-
Emeritus Professor of Law, University of Auckland, Waipapa Taumata Rau
-
Associate Professor Politics and Policy Studies, Deakin University
-
Professor of Law, Villanova University
-
Professeur des Universités, IAE Paris – Sorbonne Business School
-
Scholar Emeritus in the School of Public Health & Human Biosciences, La Trobe University
-
Senior Lecturer in Biochemistry and Cell Biology, University College Cork
-
Associate Professor and Course Leader: Post Graduate Programmes in Clinical Pharmacy in the Department of Pharmacy, Sefako Makgatho Health Sciences University
-
Senior Lecturer in International Economic Law, University of Edinburgh
-
Senior Lecturer Politics, University of Manchester
-
Professor in Intellectual Property and Innovation Law, Queensland University of Technology
-
Professor of Philosophy, Binghamton University, State University of New York
-
Professor of Economics, Loughborough University